PROEHL GERALD T - 23 Dec 2025 Form 4 Insider Report for Dermata Therapeutics, Inc. (DRMA)

Reporting relationship: PRESIDENT, CHAIRMAN, CEO, Director, 10%+ Owner
Issuer ticker: DRMA
Reported as of: 23 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 29 Dec 2025, 19:50:56 UTC
Prior SEC filing: 03 Jul 2025
Next SEC filing: 06 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Gerald T. Proehl, Attorney-in-Fact

Key filing fact

PROEHL GERALD T filed Form 4 for Dermata Therapeutics, Inc. (DRMA) on 29 Dec 2025.

Key facts

This page summarizes PROEHL GERALD T's Form 4 filing for Dermata Therapeutics, Inc. (DRMA).
8 reported transactions and 6 derivative rows are listed below.
Accepted by SEC: 29 Dec 2025, 19:50.

Change

Previous filing in this sequence was filed on 03 Jul 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001279191 Primary reporting owner

PROEHL GERALD T

Relationship: PRESIDENT, CHAIRMAN, CEO, Director, 10%+ Owner
Address: 3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO
Signature: /s/ Gerald T. Proehl, Attorney-in-Fact
Signature date: 29 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DRMA transaction

Common Stock

Award

Transaction value
Shares: +490,196
Change %: +830841%
Price
Shares after: 490,255
Date: 23 Dec 2025
Ownership: By Proehl Family Trust
Footnotes: F1, F2, F3, F6

DRMA transaction

Common Stock

Award

Transaction value
Shares: +122,549
Change %: +875350%
Price
Shares after: 122,563
Date: 23 Dec 2025
Ownership: By Sean Michael Proehl 2020 Irrevocable Trust Dated December 18, 2020
Footnotes: F1, F2, F3, F6

DRMA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 24
Date: 23 Dec 2025
Ownership: Direct
Footnotes: F3

DRMA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 7
Date: 23 Dec 2025
Ownership: By Allison Taylor Proehl 2020 Irrevocable Trust
Footnotes: F3, F6

DRMA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 3
Date: 23 Dec 2025
Ownership: By Meghan Proehl Wilder 2020 Irrevocable Trust
Footnotes: F3, F6

DRMA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 79,795
Date: 23 Dec 2025
Ownership: By Proehl Investment Ventures LLC
Footnotes: F3, F6

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DRMA transaction Derivative

Series C Warrant (Right to Buy)

Award

Transaction value
Shares: +490,196
Change %: +163399%
Price
Shares after: 490,496
Date: 23 Dec 2025
Ownership: By Proehl Family Trust
Underlying class: Common Stock
Underlying amount: 490,196
Exercise price: $2.04
Footnotes: F1, F2, F4, F6

DRMA transaction Derivative

Series D Warrant (Right to Buy)

Award

Transaction value
Shares: +490,196
Change %: +163399%
Price
Shares after: 490,496
Date: 23 Dec 2025
Ownership: By Proehl Family Trust
Underlying class: Common Stock
Underlying amount: 490,496
Exercise price: $2.04
Footnotes: F1, F2, F5, F6

DRMA transaction Derivative

Series C Warrant (Right to Buy)

Award

Transaction value
Shares: +122,549
Change %
Price
Shares after: 122,549
Date: 23 Dec 2025
Ownership: By Sean Michael Proehl 2020 Irrevocable Trust Dated December 18, 2020
Underlying class: Common Stock
Underlying amount: 122,549
Exercise price: $2.04
Footnotes: F1, F2, F4, F6

DRMA transaction Derivative

Series D Warrant (Right to Buy)

Award

Transaction value
Shares: +122,549
Change %
Price
Shares after: 122,549
Date: 23 Dec 2025
Ownership: By Sean Michael Proehl 2020 Irrevocable Trust Dated December 18, 2020
Underlying class: Common Stock
Underlying amount: 122,549
Exercise price: $2.04
Footnotes: F1, F2, F5, F6

DRMA transaction Derivative

Warrant (Right to Buy)

Disposed to Issuer

Transaction value
Shares: +78,740
Change %
Price
Shares after: 0
Date: 23 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 78,740
Exercise price: $12.70
Footnotes: F3, F7

DRMA transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +78,740
Change %
Price
Shares after: 78,740
Date: 23 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 78,740
Exercise price: $2.04
Footnotes: F3, F7

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 7 footnotes

Footnote F1

The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the "Private Placement"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Each share of common stock was purchased together with (i) a series C warrant to purchase one share of common stock and (ii) a series D warrant to purchase one share of common stock. The purchase price per share and accompanying warrants was $2.04.

Footnote F2

The purchase price per share of common stock and accompanying warrants was $2.04.

Footnote F3

Reflects a one-for-10 reverse stock split effected by the Issuer on August 1, 2025.

Footnote F4

This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common stock issuable upon exercise of the warrants. The warrant will expire five years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions.

Footnote F5

This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants. The warrant will expire two years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions.

Footnote F6

Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Footnote F7

In connection with the Private Placement, the Reporting Person entered into an amendment to an outstanding warrant issued on January 3, 2025, which amended the exercise price of the outstanding warrant from $12.70 to $2.04. This amendment is reported as the cancellation of the "old" warrant and the purchase of a replacement warrant. The warrant amendment transaction is exempt from Section 16(b) in accordance with Rule 16b-3(e) promulgated under the Exchange Act.